Application of vitexin compound in preparation of acute leukemia resisting medicine

By using vitexin compounds to inhibit leukemia cell proliferation and induce apoptosis, the problems of toxic side effects and drug resistance of existing chemotherapy drugs in the treatment of childhood acute leukemia have been solved, and more effective anti-leukemia drugs have been developed, improving the cure rate and the quality of life of children with leukemia.

CN118903099APending Publication Date: 2024-11-08THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410851421.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing chemotherapy drugs have problems with toxic side effects and multidrug resistance in the treatment of childhood acute leukemia, resulting in high treatment failure and relapse rates, and there is a lack of effective treatment options.

Method used

Vitexin compounds, including vitexin and its derivatives such as vitexin-4”-glucoside, vitexin-2”-rhamnoside, or vitexin-2”-glucoside, are used as anti-leukemia drugs. Their inhibitory effects on the proliferation and apoptosis-inducing effects on leukemia cells are studied through in vitro experiments, and drugs with stronger targeting and fewer side effects are developed.

Benefits of technology

Vitexin compounds significantly inhibit the proliferation of leukemia cells and induce apoptosis, providing a new approach to treating childhood acute leukemia, improving the cure rate and enhancing the quality of life for affected children.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903099A_ABST
    Figure CN118903099A_ABST
Patent Text Reader

Abstract

The invention discloses application of vitexin compounds in preparation of drugs for resisting acute leukemia, and belongs to the technical field of drug screening. The application of the vitexin compound in resisting acute leukemia is explored, the proliferation inhibition and apoptosis induction effects of the vitexin compound on leukemia cells are researched through in-vitro experiments, and a new thought and method are provided for treating acute leukemia. By deeply researching the action mechanism of vitexin, a novel anti-leukemia drug with stronger targeting property and smaller side effect can be developed, the cure rate of acute leukemia in children can be increased, and the life quality of sick children can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug screening, and specifically relates to the application of a vitexin compound in the preparation of an anti-acute leukemia drug. Background Art

[0002] Acute leukemia (AL) is the most common malignant tumor in children, accounting for about one-third of the total number of cancers diagnosed in children under 15 years old, of which acute lymphoblastic leukemia (ALL) accounts for about 25% and acute myeloid leukemia (AML) accounts for about 10%. In recent years, the incidence of AL has increased year by year, seriously threatening the health and life of children. Although existing chemotherapy drugs and their combined chemotherapy regimens have achieved certain results in the treatment of AL, their toxic side effects and multidrug resistance (MDR) are still serious, resulting in high rates of treatment failure and relapse.

[0003] Vitexin is a natural flavonoid compound that is widely found in many plants, especially in Vitex plants and Leguminosae plants, such as Vitex negundo and Sophorajaponica. Its structural formula is as follows:

[0004]

[0005] Vitexin has multiple biological activities, including anti-inflammatory, antioxidant, antiviral and anti-tumor effects. Studies have shown that vitexin can inhibit the growth and proliferation of tumor cells through multiple mechanisms, including inducing apoptosis, blocking the cell cycle and inhibiting tumor angiogenesis.

[0006] In recent years, vitexin has received extensive attention in anti-tumor research, and it has shown significant anti-tumor activity in a variety of tumor cells. However, there has been no research on vitexin in the treatment of acute leukemia. Summary of the invention

[0007] In view of the above-mentioned prior art, the present invention provides an application of a vitexin compound in the preparation of an anti-acute leukemia drug, so as to develop a new acute leukemia therapeutic drug.

[0008] In order to achieve the above-mentioned object, the technical solution adopted by the present invention is to provide a use of a vitexin compound in the preparation of an anti-acute leukemia drug.

[0009] Based on the above technical solution, the present invention can also be improved as follows.

[0010] Furthermore, the vitexin compound is vitexin or a vitexin derivative; the vitexin derivative is vitexin-4"-glucoside, vitexin-2"-rhamnoside or vitexin-2"-glucoside.

[0011] Furthermore, the drug is a drug that inhibits the activity of leukemia cells HL60 and / or Thp1 cells.

[0012] Furthermore, the effective concentration of the drug is 20 to 100 μM.

[0013] Furthermore, pharmaceutically acceptable salts are also included.

[0014] The beneficial effects of the present invention are as follows: the present invention explores the application of vitexin compounds in the treatment of acute leukemia, studies its proliferation inhibition and apoptosis induction effects on leukemia cells through in vitro experiments, and provides new ideas and methods for the treatment of acute leukemia. Through in-depth research on the mechanism of action of vitexin, new anti-leukemia drugs with stronger targeting and less side effects can be developed, which is helpful to improve the cure rate of acute leukemia in children and improve the quality of life of children with the disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is a graph showing the changes in cell viability of leukemia cell HL60 treated with different concentrations of vitexin;

[0016] Figure 2 The results of flow cytometry apoptosis detection of HL60 cells after vitexin treatment for 24 hours;

[0017] Figure 3 This is a graph showing the changes in cell viability of leukemia cell Thp1 treated with different concentrations of vitexin;

[0018] Figure 4 The results of flow cytometry apoptosis detection of Thp1 cells after vitexin treatment for 24 hours. DETAILED DESCRIPTION

[0019] The reagents used in the present invention are as follows:

[0020] Reagents company nation Fetal bovine serum VivaCell China RPMI 1640 Gibco China penicillin Gibco China Streptomycin Gibco China CCK-8 Kit APExBIO USA 1000μL, 200μL, 10μL Tips Axygen USA 1.5mL EP tube Axygen USA Apoptosis Kit BD USA Leukemia cell line HL60 Shanghai Yingwan Biotechnology Co., Ltd. China Thp1 cells Shanghai Yingwan Biotechnology Co., Ltd. China

[0021] The preparation method of the culture medium used in the present invention is:

[0022] For every 100 mL of cell culture medium: take 89 mL of RPMI 1640, add 10 mL of fetal bovine serum, then add 1 mL of double antibody, mix well, and store at 4°C.

[0023] The specific implementation modes of the present invention are described in detail below with reference to the embodiments.

[0024] Example 1: Inhibitory effect of vitexin on proliferation of leukemia cells HL60

[0025] (1) taking leukemia HL60 cells, inoculating them into culture medium, and culturing them to the logarithmic phase under the conditions of 37° C., 5% CO 2 , and 90% humidity;

[0026] (2) HL60 cells in logarithmic phase growth were taken and inoculated into a 96-well plate containing culture medium at a rate of 20,000 cells / well. Vitexin with a final concentration of 10, 20, 40, 60, 80, and 100 μM and an equal volume of DMSO (dimethyl sulfoxide, the final concentration of which was controlled below 1‰ (v / v)) were added to the experimental groups, respectively. 10 μL of serum-free RPMI 1640 culture medium was added to the negative control group, and a blank zero adjustment group was set up, with 3 replicate wells in each group. The 96-well plate was then placed in a constant temperature cell culture incubator and cultured at 37°C, 5% CO2, and 90% humidity for 24 hours. Subsequently, 10 μL of CCK8 solution was added to each well, and the cells were incubated at 37°C, 5% CO2 for 4 hours. The absorbance OD value of each well was then detected at 450 nm using an ELISA reader. The average OD value of each group was calculated, and the cell proliferation inhibition rate was calculated according to the following formula:

[0027] Proliferation inhibition rate (%) = (OD value of control group - OD value of experimental group) / (OD value of control group - OD value of blank group) × 100%

[0028] Fitting the cell activity curve, the results are as follows Figure 1 As shown in the figure, it can be seen that vitexin can significantly inhibit the proliferation of HL60 cells.

[0029] Example 2: Apoptosis-inducing effect of vitexin on leukemia cells HL60

[0030] (1) Inoculate 1 mL of culture medium in a 6-well plate at a density of (5-10)×10 5 HL60 cells in logarithmic phase with a concentration of 10 μM / mL were added with vitexin to make the final concentrations of 20, 40, and 60 μM, respectively; the cells were cultured at 37°C, 5% CO2, and 90% humidity for 24 hours, and the cells were collected after 24 hours;

[0031] (2) Follow the steps of the Annexin V / PI cell apoptosis kit, wash the cells twice with PBS, then resuspend the cells in 400 μL of 1× Binding buffer, add 5 μL of Annexin-VFITC and 5 μL of propidium iodide, and detect the cell apoptosis rate by flow cytometry. The results are as follows: Figure 2As shown in the figure, it can be seen that vitexin can significantly induce apoptosis of HL60 cells, and the apoptosis rate increases significantly with the increase of vitexin concentration, and the highest apoptosis rate reaches 53.41%.

[0032] Example 3: Inhibitory effect of vitexin on proliferation of leukemia cells Thp1

[0033] (1) Thp1 cells were taken and inoculated into culture medium, and cultured to the logarithmic phase under the conditions of 37°C, 5% CO2, and 90% humidity;

[0034] (2) Take Thp1 cells in logarithmic phase and inoculate them into 96-well plates containing culture medium at a rate of 20,000 cells / well. The experimental groups were added with final concentrations of 10, 20, 40, 60, 80, and 100 μM of vitexin and an equal volume of DMSO (dimethyl sulfoxide, the final concentration of which was controlled below 1‰ (v / v)), respectively. The negative control group was added with 10 μL of serum-free RPMI 1640 culture medium, and a blank zero adjustment group was set up, with 3 replicate wells in each group. Then the 96-well plate was placed in a constant temperature cell culture incubator and cultured at 37°C, 5% CO2, and 90% humidity for 24 hours. Subsequently, 10 μL of CCK8 solution was added to each well and incubated at 37°C, 5% CO2 for 4 hours. The absorbance OD value of each well was then detected at 450 nm using an enzyme reader. The average OD value of each group was calculated, and the cell proliferation inhibition rate was calculated according to the following formula:

[0035] Proliferation inhibition rate (%) = (OD value of control group - OD value of experimental group) / (OD value of control group - OD value of blank group) × 100%

[0036] Fitting cell activity curves, such as Figure 3 As shown in the figure, it can be seen that vitexin can significantly inhibit the proliferation of Thp1 cells.

[0037] Example 4: Apoptosis-inducing effect of vitexin on leukemia cell Thp1

[0038] (1) Inoculate 1 mL of the solution in a 6-well plate at a density of (5-10)×10 5 Thp1 cells growing in logarithmic phase at 1 μM / mL were added with vitexin to make the final concentrations of 20, 40, and 60 μM, respectively; the cells were cultured at 37°C, 5% CO2, and 90% humidity for 24 hours, and the cells were collected after 24 hours;

[0039] (2) Follow the steps of the Annexin V / PI cell apoptosis kit, wash the cells twice with PBS, then resuspend the cells in 400 μL of 1× Binding buffer, add 5 μL of Annexin-VFITC and 5 μL of propidium iodide, and detect the cell apoptosis rate by flow cytometry. The results are as follows: Figure 4 As shown in the figure, it can be seen that vitexin can significantly induce apoptosis of Thp1 cells, and the apoptosis rate increases significantly with the increase of vitexin concentration, and the highest apoptosis rate reaches 48.77%.

[0040] Although the specific implementation of the present invention is described in detail in conjunction with the embodiments, it should not be understood as limiting the scope of protection of this patent. Within the scope described in the claims, various modifications and variations that can be made by those skilled in the art without creative work still fall within the scope of protection of this patent.

Claims

1. Application of vitexin compounds in the preparation of drugs against acute leukemia.

2. The use according to claim 1, Features: The vitexin compound is vitexin or a vitexin derivative; the vitexin derivative is vitexin-4"-glucoside, vitexin-2"-rhamnoside or vitexin-2"-glucoside.

3. The use according to claim 1, Features: The drug is a drug for inhibiting the activity of leukemia cells HL60 and / or Thp1 cells.

4. The use according to claim 3, Features: The effective concentration of the drug is 20-100 μM.

5. The use according to claim 4, Features: Pharmaceutically acceptable salts are also included.